Drug Approval | June 03, 2026
FDA fast-tracks Roche’s giredestrant review as data signal potential shift in early breast cancer care
The filing is backed by Phase III data from the lidERA Breast Cancer study
The filing is backed by Phase III data from the lidERA Breast Cancer study
The companies say the drug has now demonstrated clinical benefit in three separate Phase 3 trials
Eribulin Mesylate Injection, 1 mg/2 mL (0.5 mg/mL) single-dose vials is the bioequivalent to the reference listed drug (RLD) Halaven injection of Eisai, Inc.
The initiative opens pathways for female students to pursue healthcare programs across 20+ top universities and colleges in India
Novel fluorescent nanosensor enables real-time detection of indole-3-propionic acid (IPA), paving the way for faster gut health screening, point-of-care diagnostics, and wearable monitoring devices
Anti-GD2 monoclonal antibody for high-risk neuroblastoma advances toward BLA submission following successful tech transfer from California to Bengaluru
AI-enabled wearable remote patient monitoring platform successfully completed pilot deployments in a government super-specialty hospital and emergency ambulances
The therapy also delivered significant improvements in key liver enzyme markers
We have the chance to build an IP estate that goes hand in hand with our generic pharmaceutical strength and build proprietary biological platforms
Derived from rice bran wax, Licocare RBW products offer a renewable solution with a substantially lower carbon footprint than conventional montan waxes
Subscribe To Our Newsletter & Stay Updated
